Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2021-10-07 00:00:00 ET · period of report 2021-10-05 · accession 0001209191-21-059984 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-07 | 2021-10-05 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | S - Sale+OE | $98.50 | -4,963 | 60.0K | -8% | -$488.9K |
| D | 2021-10-07 | 2021-10-05 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $54.85 | +4,963 | 65.0K | +8% | +$272.2K |
| D | 2021-10-07 | 2021-10-05 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $0.00 | -4,963 | 95.0K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-05 | S | D | 4,963 | $98.50 | 60,000 | D | — | — | |
| 2 | Common | Common Stock | 2021-10-05 | M | A | 4,963 | $54.85 | 64,963 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-10-05 | M | D | 4,963 | $0.00 | 95,037 | D | $54.85 · — to 2030-02-05 | 4,963 Common Stock | (F2) 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. |